medcelerator · clinician one-pager
New Daily Pill for Adult Muscle and Skin Inflammation
Lisraya (brepocitinib) — first oral TYK2/JAK1 tablet labelled for adult dermatomyositis
FDA Approved · United States, Canada · September 4, 2026
Condition: Dermatomyositis
Who this is for
FDA labelled a once-daily 30 mg pill for dermatomyositis in adults (27 August 2026), with a boxed JAK-class warning. Health Canada NOC was not retrieved — Canada is not dual-approved. As of 10 October 2026, VALOR is completed (no longer enrolling). Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In Canada, authorisation is not confirmed; see Possible routes below if any are listed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5023a17b-e96a-67d4-e063-6394a90a14a7&version=3
Possible routes (not confirmed)
Canada · Health Canada Special Access Programme (SAP) · Applicability unknown
Health Canada Special Access Programme (manufacturer must agree)
SAP here depends on the manufacturer agreeing to supply; no confirmation for this drug.
https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html
General resources for further research
Canadian Clinical Trial Search Portal (Health Canada)
Health Canada's public search of the drug and biologic clinical trials it has authorised in Canada (phase 1 to 3, since April 2013). Search by condition, drug, or trial status and see where trials are running. It replaced the Health Canada Clinical Trials Database in July 2026. A listing is not enrolment, and Health Canada does not recruit patients: ask your clinician and contact the trial sponsor.
https://clinical-trials-search.canada.ca/en/home
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/lisraya-brepocitinib